Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours Β· Estimated delivery Aug 19 - Aug 24
Acta Epileptol 5:28
not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
Mucosal ribosomal stress-induced PRDM1 promotes chemoresistance via stemness regulation
For some, the switch could mean the difference between good and great, between improvement and transformation
